Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have received a consensus rating of "Buy" from the ten research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $20.89.

A number of analysts have issued reports on the stock. Wedbush reissued an "outperform" rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. HC Wainwright reissued a "buy" rating on shares of Y-mAbs Therapeutics in a report on Wednesday, December 11th. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a "buy" rating and a $17.00 price objective for the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Finally, Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an "outperform" rating and a $23.00 price target on the stock.

Y-mAbs Therapeutics Stock Up 5.2 %

Shares of NASDAQ YMAB traded up $0.49 during midday trading on Monday, hitting $9.92. 373,341 shares of the company's stock were exchanged, compared to its average volume of 325,028. Y-mAbs Therapeutics has a 12 month low of $6.09 and a 12 month high of $20.90. The company's 50 day moving average price is $12.79 and its 200 day moving average price is $12.67. The firm has a market capitalization of $444.32 million, a PE ratio of -18.37 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). The company had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter last year, the company posted ($0.18) EPS. On average, equities research analysts anticipate that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of YMAB. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Y-mAbs Therapeutics during the 3rd quarter worth approximately $44,000. China Universal Asset Management Co. Ltd. raised its position in shares of Y-mAbs Therapeutics by 66.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company's stock worth $113,000 after acquiring an additional 3,416 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Y-mAbs Therapeutics in the third quarter worth approximately $133,000. SG Americas Securities LLC bought a new stake in Y-mAbs Therapeutics in the third quarter valued at approximately $178,000. Finally, Empire Financial Management Company LLC acquired a new stake in shares of Y-mAbs Therapeutics during the third quarter worth $210,000. Institutional investors and hedge funds own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.